Abstract
Subtilisin QK, a new fibrinolytic enzyme, could cleave directly cross-linked fibrin in vitro. To verify the thrombolytic function of Subtilisin QK in vivo, the thrombolytic effect of purified Subtilisin QK on tail-thrombus of mouse was investigated. After injected with carrageenan, the tail-thrombus of Subtilisin QK treated group were shorter than the physiological saline treated group. Moreover, the tail-thrombus decreased correlate with Subtilisin QK in a dose-dependent manner. Thrombus nearly disappeared while the mice were treated with 12000 IU Subtilisin QK. The result indicated that Subtilisin QK significantly inhibited thrombus formation in mouse tail. This study made more foundation for further development of Subtilisin QK as a novel bifunctional thrombolytic agent.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- tPA:
-
Tissue plasminogen activator
- MW:
-
Molecular weight
- SDS-PAGE:
-
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
- rTFPI:
-
Recombinant human tissue factor pathway inhibitor
- ScFV:
-
Single-chain variable fragment
References
Hsiao G, Yen MH, Lee YM, Sheu JR (2002) Antithrombotic effect of PMC, a potent alpha-tocopherol analogue on platelet plug formation in vivo. Br J Haematol 117:699–704. doi:10.1046/j.1365-2141.2002.03492.x
Jorgensen L (2006) The role of platelets in the initial stages of atherosclerosis. J Thromb Haemost 4:1443–1449. doi:10.1111/j.1538-7836.2006.02006.x
Boisseau MR (1997) Venous valves in the legs: hemodynamic and biological problems and relationship to physiopathology. J Mal Vasc 22:122–127
Selwyn A (2003) Prothrombotic and antithrombotic pathways in acute coronary syndromes. Am J Cardiol 91(12):3–11. doi:10.1016/S0002-9149(03)00428-4
Plow EF, Hoover-Plow J (2004) The functions of plasminogen in cardiovascular disease. Trends Cardiovasc Med 14:180–186. doi:10.1016/j.tcm.2004.04.001
Ko JH, Yan JP, Zhu L, Qi YP (2004) Identification of two novel fibrinolytic enzymes from Bacillus subtilis QK02. Comp Biochem Physiol C Toxicol Pharmacol 137:65–74. doi:10.1016/j.cca.2003.11.008
Ko J, Yan J, Zhu L, Qi Y (2005) Subtilisin QK, a fibrinolytic enzyme, inhibits the exogenous nitrite and hydrogen peroxide induced protein nitration, in vitro and in vivo. J Biochem Mol Biol 38:577–583
Verbeuren TJ (2006) Experimental models of thrombosis and atherosclerosis. Therapie 61:379–387. doi:10.2515/therapie:2006069
Bekemeier H, Hirschelmann R, Giessler AJ (1984) Carrageenan-induced thrombosis in the rat and mouse as a test model of substances influencing thrombosis. Biomed Biochim Acta 43(8–9):S347–S350
Bekemeier H, Hirschelmann R, Giessler AJ (1985) Carrageenin-induced thrombosis in rats and mice: A model for testing antithrombotic substances? Agents Actions 16:449–451. doi:10.1007/BF01982887
Kod’ousek R, Jezdinsk J, Krajci D (2007) Histological and ultrastructural changes of cardiomyocytes in experimental rats with tail thrombosis following subplantar application of carrageenin. Med Princ Pract 16:360–366. doi:10.1159/000104809
Hansra P, Moran EL, Fornasier VL, Bogoch ER (2000) Carrageenan-induced arthritis in the rat. Inflammation 24:141–155. doi:10.1023/A:1007033610430
Gervasi GB, Bartoli C, Carpita G (1991) A new low molecular weight heparan sulphate antagonizes kappa-carrageenan-induced thrombosis in rats. Pharmacol Res 24:59–63. doi:10.1016/1043-6618(91)90065-6
Hirschelmann R, Bekemeier H (1986) Heparin and phenprocoumon inhibit kappa-carrageenan induced thrombosis in rats. Folia Haematol Int Mag Klin Morphol Blutforsch 113:379–382
Hu S, Tian Q, Gu J, Sha J, Zhao D, Yan P et al (1993) A new kind of thrombus formation animal model in vivo. Zhonghua Xue Ye Xue Za Zhi 14:541–542
Astrup T, Mullertz S (1952) The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys 40:346–351. doi:10.1016/0003-9861(52)90121-5
Di Rosa M (1972) Biological properties of carrageenan. J Pharm Pharmacol 24:89–102
Liang AH, Ding XS, Li W, Xue BY, Wang JH, Yang HJ (2005) Development of an animal model of blood stasis syndrome and thrombosis. Zhongguo Zhong Yao Za Zhi 30:1613–1616
Elsayed YA, Nakagawa K, Kamikubo YI, Enjyoji KI, Kato H, Sueishi K (1996) Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model. Am J Clin Pathol 106:574–583
Bertelli A, Bertelli AA, Giovannini L (1994) The potentiating effect of propionyl carnitine on prostacycline prevention of thrombosis induced by endothelin (ET-1) and K-carrageenan. Drugs Exp Clin Res 20:7–11
Bekemeier H, Gabor M, Hirschelmann R (1990) Influence of flavonoids and lanthanides on kappa-carrageenan rat tail thrombosis. Exp Pathol 40:61–63
Wang LL, Li ZC, Mei QB, Zhao DH (2000) MN9202 protection of tail artery in carrageenan induced thrombos is rats. J Fourth Mil Med Univ 21(2):214–216; Chinese
Yan JP, Ko JH, Qi YP (2004) Generation and characterization of a novel single-chain antibody fragment specific against human fibrin clots from phage display antibody library. Thromb Res 114:205–211. doi:10.1016/j.thromres.2004.06.013
Author information
Authors and Affiliations
Corresponding authors
Additional information
F. Yan and J. Yan contributed equally to this work.
Rights and permissions
About this article
Cite this article
Yan, F., Yan, J., Sun, W. et al. Thrombolytic effect of Subtilisin QK on carrageenan induced thrombosis model in mice. J Thromb Thrombolysis 28, 444–448 (2009). https://doi.org/10.1007/s11239-009-0333-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-009-0333-3